Simcere Pharmaceutical Group (NYSE: SCR) reported earnings on May 9. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Simcere Pharmaceutical Group missed estimates on revenues and met expectations on earnings per share.

Compared with the prior-year quarter, revenue grew and GAAP earnings per share didn't change.

Gross margins shrank, operating margins improved, net margins grew.

Revenue details
Simcere Pharmaceutical Group recorded revenue of $77.3 million. The three analysts polled by S&P Capital IQ predicted sales of $82.3 million on the same basis. GAAP reported sales were 5.1% higher than the prior-year quarter's $73.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.08. The one earnings estimate compiled by S&P Capital IQ averaged $0.08 per share. GAAP EPS of $0.08 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 82.0%, 190 basis points worse than the prior-year quarter. Operating margin was 8.9%, 280 basis points better than the prior-year quarter. Net margin was 5.9%, 10 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $88.5 million. On the bottom line, the average EPS estimate is $0.13.

Next year's average estimate for revenue is $343.5 million. The average EPS estimate is $0.38.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 232 members out of 243 rating the stock outperform, and 11 members rating it underperform. Among 41 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 38 give Simcere Pharmaceutical Group a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group is hold, with an average price target of $9.08.

Over the decades, small-cap stocks like Simcere Pharmaceutical Group have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.